Get the Stockscreener App
78.53
7.18%
5.26
Ptc Therapeutics Inc stock is traded at $78.53, with a volume of 3.19M.
It is up +7.18% in the last 24 hours and up +9.88% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
See More
Previous Close:
$73.27
Open:
$75.56
24h Volume:
3.19M
Relative Volume:
2.55
Market Cap:
$6.51B
Revenue:
$1.73B
Net Income/Loss:
$682.64M
P/E Ratio:
10.15
EPS:
7.7364
Net Cash Flow:
$411.18M
1W Performance:
+7.06%
1M Performance:
+9.88%
6M Performance:
+4.79%
1Y Performance:
+54.43%
1-Day Range:
$74.86
$79.60
1-Week Range:
$71.80
$79.60
52-Week Range:
$43.17
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
78.53 | 6.37B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
[8-K] PTC THERAPEUTICS, INC. Reports Material Event - Stock Titan
PTC Therapeutics prices convertible notes for refinancing - MSN
PTC Therapeutics (PTCT) Launches $500M Convertible Notes Offerin - GuruFocus
PTC Therapeutics Prices $500 Million Notes Offering - marketscreener.com
Biotech PTC sells $500M 0% notes at 40% premium to stock - Stock Titan
PTC Therapeutics Prices $500 Million 0% Convertible Senior Notes Due 2031 - TradingView
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes - TradingView
PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes - marketscreener.com
PTC Therapeutics plans $500M notes to refinance 2026 debt, buy stock - Stock Titan
PTC Therapeutics Q1 earnings call highlights - MSN
PTC Therapeutics Insider Sold Shares Worth $1,595,775, According to a Recent SEC Filing - Moomoo
PTC Therapeutics climbs after guidance hike - MSN
96,860 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Castleark Management LLC - MarketBeat
Insider Sell: Eric Pauwels Sells 21,277 Shares of PTC Therapeuti - GuruFocus
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock - Investing.com UK
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock By Investing.com - Investing.com South Africa
PTC Therapeutics (PTCT) CBO sells shares under 10b5-1 trading plan - Stock Titan
Sector Gamma AS Sells 56,189 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup - ChartMill
Fidelity affiliate seeks to sell PTCT (NASDAQ: PTCT) 17,566 shares on 06/10/2026 - Stock Titan
PTC Therapeutics upgraded at Jefferies on Sephience - MSN
Los Angeles Capital Management LLC Has $2.46 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Key facts: PTC Therapeutics director resigns; posts record revenue - TradingView
PTC Therapeutics Director Resigns, Moves to Advisory Role - TipRanks
Alethia Young resigns from PTC Board, to serve as consultant - TradingView
PTC Therapeutics (NASDAQ: PTCT) director Alethia Young shifts to consultant role - Stock Titan
PTC Therapeutics Shares Rise After Upgrade From Citigroup - Moomoo
Transcript : PTC Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com
PTCT Raised by Citigroup -- Price Target Increased to $108 - GuruFocus
PTC Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76 - marketscreener.com
PTC Therapeutics (PTCT) reports Q1 loss, tops revenue estimates - MSN
19,877 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS - MarketBeat
A Look At PTC Therapeutics (PTCT) Valuation As Models Flag A Potential Discount - Sahm
Why The PTC Therapeutics (PTCT) Story Is Shifting As Sephience Assumptions Drive New Valuations - Yahoo Finance
Total operating expenses of PTC Therapeutics, Inc. – XETR:BH3 - TradingView
BI Asset Management Fondsmaeglerselskab A S Purchases 64,472 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Gross profit of PTC Therapeutics, Inc. – XETR:BH3 - TradingView
PTC Therapeutics Shareholders Back Board, Pay and Auditor - The Globe and Mail
Total debt per share of PTC Therapeutics, Inc. – XETR:BH3 - TradingView
PTC Therapeutics, Inc. Cash Flow – XETR:BH3 - TradingView
ETFs Investing in PTC Therapeutics, Inc. Stocks - TradingView
PTC Therapeutics, Inc. 8-K Filing June 2026 – Company Information, Stock Details, and SEC Compliance - Minichart
Precision Trading with Ptc Therapeutics Inc. (PTCT) Risk Zones - Stock Traders Daily
PTC Therapeutics (NASDAQ: PTCT) investors approve directors, auditor and pay at 2026 meeting - Stock Titan
Geode Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market Shows Strong Future Potential with - openPR.com
PTC Therapeutics Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
PTC Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ptc Therapeutics Inc Stock (PTCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jun 10 '26 |
Sale |
75.00 |
21,277 |
1,595,775 |
73,411 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):